×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
APRE – aprea therapeutics, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
APRE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/4
08:30 am
apre
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
Low
Report
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
1/29
01:02 pm
apre
Aprea Therapeutics (NASDAQ:APRE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock, down previously from $5.00.
Low
Report
Aprea Therapeutics (NASDAQ:APRE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock, down previously from $5.00.
1/29
08:27 am
apre
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
High
Report
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
1/29
08:25 am
apre
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules
High
Report
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules
1/23
05:06 am
apre
Aprea Therapeutics (NASDAQ:APRE) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Aprea Therapeutics (NASDAQ:APRE) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
1/15
07:46 am
apre
Aprea Therapeutics (NASDAQ:APRE) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
Aprea Therapeutics (NASDAQ:APRE) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
12/18
12:14 pm
apre
Aprea Therapeutics (NASDAQ:APRE) had its price target lowered by analysts at HC Wainwright from $20.00 to $5.00. They now have a "buy" rating on the stock.
Low
Report
Aprea Therapeutics (NASDAQ:APRE) had its price target lowered by analysts at HC Wainwright from $20.00 to $5.00. They now have a "buy" rating on the stock.
12/18
08:30 am
apre
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
Low
Report
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/2
04:08 pm
apre
Form 4 Aprea Therapeutics, Inc. For: Jan 30 Filed by: Gilad Oren
High
Report
Form 4 Aprea Therapeutics, Inc. For: Jan 30 Filed by: Gilad Oren
2/2
04:06 pm
apre
Form 4 Aprea Therapeutics, Inc. For: Jan 30 Filed by: Hamill John P.
High
Report
Form 4 Aprea Therapeutics, Inc. For: Jan 30 Filed by: Hamill John P.
1/29
04:17 pm
apre
Form 8-K Aprea Therapeutics, Inc. For: Jan 28
High
Report
Form 8-K Aprea Therapeutics, Inc. For: Jan 28
1/28
02:02 pm
apre
Form SCHEDULE 13G/A Aprea Therapeutics, Inc. Filed by: HIRSCHMAN ORIN
Medium
Report
Form SCHEDULE 13G/A Aprea Therapeutics, Inc. Filed by: HIRSCHMAN ORIN
1/23
04:46 pm
apre
Form 8-K Aprea Therapeutics, Inc. For: Jan 23
Low
Report
Form 8-K Aprea Therapeutics, Inc. For: Jan 23
1/9
04:31 pm
apre
Form 8-K Aprea Therapeutics, Inc. For: Jan 09
Low
Report
Form 8-K Aprea Therapeutics, Inc. For: Jan 09
12/30
06:04 am
apre
Form EFFECT Aprea Therapeutics, Inc.
Medium
Report
Form EFFECT Aprea Therapeutics, Inc.
12/30
06:01 am
apre
Form 424B3 Aprea Therapeutics, Inc.
Medium
Report
Form 424B3 Aprea Therapeutics, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/2
Form 3 Aprea Therapeutics, Inc. For: Oct 02 Filed by: Coiante Scott M
32.6%
11/14 Aprea Therapeutics (NASDAQ: APRE) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 10.6%
12/12 Recap and Update of Positive Data from Phase Ib/II Clinical Trials of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2019 American Society of Hematology (ASH) An 9.3%
3/27 Aprea Therapeutics (NASDAQ: APRE) had its "hold" rating re-affirmed by analysts at Morgan Stanley. They now have a $36.00 price target on the stock. 9.1%
4/3 Form 8-K Aprea Therapeutics, Inc. For: Apr 03 6.5%
10/7 U.S. IPO Weekly Recap: Oncology Biotech Aprea Therapeutics Finishes On Top In 4-IPO Week [Seeking Alpha] 6.2%
10/17 Form SC 13D Aprea Therapeutics, Inc. Filed by: 5AM Ventures IV, L.P. 4.5%
1/13 Form 8-K Aprea Therapeutics, Inc. For: Jan 13 3.6%
10/9 Form 4 Aprea Therapeutics, Inc. For: Oct 07 Filed by: Schwab Andrew J. 2.1%
11/18 Form S-8 Aprea Therapeutics, Inc. 2.0%
11/14 Aprea Therapeutics (NASDAQ: APRE) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 10.6%
12/12 Recap and Update of Positive Data from Phase Ib/II Clinical Trials of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2019 American Society of Hematology (ASH) An 9.3%
3/27 Aprea Therapeutics (NASDAQ: APRE) had its "hold" rating re-affirmed by analysts at Morgan Stanley. They now have a $36.00 price target on the stock. 9.1%
4/3 Form 8-K Aprea Therapeutics, Inc. For: Apr 03 6.5%
10/7 U.S. IPO Weekly Recap: Oncology Biotech Aprea Therapeutics Finishes On Top In 4-IPO Week [Seeking Alpha] 6.2%
10/17 Form SC 13D Aprea Therapeutics, Inc. Filed by: 5AM Ventures IV, L.P. 4.5%
1/13 Form 8-K Aprea Therapeutics, Inc. For: Jan 13 3.6%
10/9 Form 4 Aprea Therapeutics, Inc. For: Oct 07 Filed by: Schwab Andrew J. 2.1%
11/18 Form S-8 Aprea Therapeutics, Inc. 2.0%
TOP News Decliners
3/26
Q4/2019 12/31/2019 EPS -0.640 ZacksConsensus -0.390 ActVsEst (0.250) - Miss
-11.5%
10/4 Form 424B4 Aprea Therapeutics, Inc. -8.7%
12/9 Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual -7.7%
10/7 Form 4 Aprea Therapeutics, Inc. For: Oct 07 Filed by: Seizinger Bernd R. -7.6%
4/29 Form DEFA14A Aprea Therapeutics, Inc. -5.6%
2/14 Form SC 13G Aprea Therapeutics, Inc. Filed by: KDev Investments AB -4.6%
2/13 Aprea Therapeutics Appoints Gregory S. Wessels as Vice President, Commercial -4.1%
10/28 Aprea Therapeutics (NASDAQ: APRE) is now covered by analysts at JPMorgan Chase & Co.. They set a "neutral" rating on the stock. -2.8%
11/12 Form SC 13G Aprea Therapeutics, Inc. Filed by: FMR LLC -2.4%
1/9 Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 -2.1%
10/4 Form 424B4 Aprea Therapeutics, Inc. -8.7%
12/9 Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual -7.7%
10/7 Form 4 Aprea Therapeutics, Inc. For: Oct 07 Filed by: Seizinger Bernd R. -7.6%
4/29 Form DEFA14A Aprea Therapeutics, Inc. -5.6%
2/14 Form SC 13G Aprea Therapeutics, Inc. Filed by: KDev Investments AB -4.6%
2/13 Aprea Therapeutics Appoints Gregory S. Wessels as Vice President, Commercial -4.1%
10/28 Aprea Therapeutics (NASDAQ: APRE) is now covered by analysts at JPMorgan Chase & Co.. They set a "neutral" rating on the stock. -2.8%
11/12 Form SC 13G Aprea Therapeutics, Inc. Filed by: FMR LLC -2.4%
1/9 Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 -2.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: